Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors

Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage resp...

Full description

Bibliographic Details
Main Authors: Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Current Oncology
Subjects:
DNA damage response
immune checkpoint inhibitors
<i>BRCA1</i>
<i>BRCA2</i>
<i>CHEK2</i>
Online Access:https://www.mdpi.com/1718-7729/28/5/280

Internet

https://www.mdpi.com/1718-7729/28/5/280

Similar Items